AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE

AstraZeneca's chief exec publicly criticized the U.K.'s tax policies last month, but that didn't stop officials there from backing the company's key asthma launch.

England's National Institute for Health and Care Excellence (NICE) has issued final draft guidance in support of AstraZeneca and Amgen's Tezspire as a maintenance treatment for people 12 and older with severe asthma. Pending a final signoff, the drug looks set to be available to tens of thousands of severe asthma sufferers in England.